Recital 13, Regulation (EU) 2024/1052

In forcesince 10 Apr 2024

In its report, the Authority concluded that the novel food calcidiol monohydrate proposed for use in food supplements is a bioavailable source of the biologically active metabolite of vitamin D (1,25-dihydroxyvitamin D) and that a conversion factor of 2,5 reflects the relative bioavailability of calcidiol monohydrate as compared to vitamin D3 under the proposed conditions of use and use levels. The Authority further concluded that the novel food calcidiol monohydrate proposed for use in food supplements is safe under the proposed conditions of use and use levels (up to 10 μg/day) for children from 11 years of age and for adults, including pregnant and lactating women, as well as under the proposed conditions of use and use levels (up to 5 μg/day) for children from 3 to 10 years of age.